Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Adding Metformin to Growth Hormone Therapy on Cardiovascular Risk Markers in Prepubertal Children Born Small for Gestational Age Without Postnatal Catch-up Growth
2009-016246-12Phase 2Active
- Sponsor
- Sant Joan de Déu Hospital
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of metformin in Small for gestational age (SGA), insulin resistance (IR) and cardiometabolic risk (CMR), sponsored by Sant Joan de Déu Hospital. Primary endpoint: Prevention of insulin resistance. Started Nov 2009; status: active.
02
Drugs
metformin
03
Conditions
Small for gestational age (SGA)insulin resistance (IR)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2009-016246-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016246-12.